Literature DB >> 16127080

In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases.

Luciana Trilles1, Belkys Fernández-Torres, Márcia Dos Santos Lazéra, Bodo Wanke, Armando de Oliveira Schubach, Rodrigo de Almeida Paes, Isabel Inza, Josep Guarro.   

Abstract

We have determined the antifungal susceptibilities of 34 clinical isolates of the dimorphic fungus Sporothrix schenckii to 11 drugs using a microdilution method. In general, the type of growth phase (mycelial or yeast) and the temperature of incubation (30 or 35 degrees C) exerted a significant influence on the MICs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127080      PMCID: PMC1195444          DOI: 10.1128/AAC.49.9.3952-3954.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Sporotrichosis.

Authors:  R Morris-Jones
Journal:  Clin Exp Dermatol       Date:  2002-09       Impact factor: 3.470

2.  Physiological characters of Sporothrix schenckii isolates.

Authors:  A Ghosh; P K Maity; B M Hemashettar; V K Sharma; A Chakrabarti
Journal:  Mycoses       Date:  2002-12       Impact factor: 4.377

3.  In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine.

Authors:  Lidiane Meire Kohler; Paulo César Fialho Monteiro; Rosane Christine Hahn; Júnia Soares Hamdan
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

Review 4.  [A case of lymphocutaneous sporotrichosis].

Authors:  N Morishita; K Yamazaki; J Ninomiya; T Hamaguchi; Y Sei; I Takiuchi
Journal:  Nihon Ishinkin Gakkai Zasshi       Date:  2001

5.  Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B.

Authors:  M R McGinnis; N Nordoff; R K Li; L Pasarell; D W Warnock
Journal:  Med Mycol       Date:  2001-08       Impact factor: 4.076

6.  Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole.

Authors:  S Shadomy; S C White; H P Yu; W E Dismukes
Journal:  J Infect Dis       Date:  1985-12       Impact factor: 5.226

7.  In vitro antifungal susceptibility of Cryptococcus gattii.

Authors:  Luciana Trilles; Belkys Fernández-Torres; Márcia dos Santos Lazéra; Bodo Wanke; Josep Guarro
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

8.  Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis.

Authors:  S W Chapman; P Pappas; C Kauffmann; E B Smith; R Dietze; N Tiraboschi-Foss; A Restrepo; A B Bustamante; C Opper; S Emady-Azar; R Bakshi
Journal:  Mycoses       Date:  2004-02       Impact factor: 4.377

9.  In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes.

Authors:  Belkys Fernández-Torres; Isabel Inza; Josep Guarro
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

10.  In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.

Authors:  Toru Nakai; Jun Uno; Fumiaki Ikeda; Shuichi Tawara; Kazuko Nishimura; Makoto Miyaji
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more
  14 in total

1.  Evaluation of the origin of a sample of Sporothrix schenckii that caused contamination of a researcher in Southern Brazil.

Authors:  Melissa Fontes Landell; Cheila Denise Ottonelli Stopiglia; Raisa G Billodre; Daiane Heidrich; Julia Medeiros Sorrentino; Marilene H Vainstein; Maria Lúcia Scroferneker; Patricia Valente
Journal:  Mycopathologia       Date:  2010-09-12       Impact factor: 2.574

2.  In vitro antifungal susceptibility of Sporothrix globosa isolates from Jilin Province, northeastern China: comparison of yeast and mycelial phases.

Authors:  Yang Song; Shanshan Li; Ying Shi; Lipei Zhao; Yu Cui; Lei Yao; Yu Zhen; Ruili Chen; Yan Cui
Journal:  Braz J Microbiol       Date:  2020-06-17       Impact factor: 2.476

3.  Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods.

Authors:  A Espinel-Ingroff; D P B Abreu; R Almeida-Paes; R S N Brilhante; A Chakrabarti; A Chowdhary; F Hagen; S Córdoba; G M Gonzalez; N P Govender; J Guarro; E M Johnson; S E Kidd; S A Pereira; A M Rodrigues; S Rozental; M W Szeszs; R Ballesté Alaniz; A Bonifaz; L X Bonfietti; L P Borba-Santos; J Capilla; A L Colombo; M Dolande; M G Isla; M S C Melhem; A C Mesa-Arango; M M E Oliveira; M M Panizo; Z Pires de Camargo; R M Zancope-Oliveira; J F Meis; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  Evolution of virulence-related phenotypes of Sporothrix brasiliensis isolates from patients with chronic sporotrichosis and acquired immunodeficiency syndrome.

Authors:  Ingrid Ludmila Rodrigues Cruz; Dayvison Francis Saraiva Freitas; Priscila Marques de Macedo; Maria Clara Gutierrez-Galhardo; Antonio Carlos Francesconi do Valle; Marcos de Abreu Almeida; Rowena Alves Coelho; Fábio Brito-Santos; Maria Helena Galdino Figueiredo-Carvalho; Rosely Maria Zancopé-Oliveira; Rodrigo Almeida-Paes
Journal:  Braz J Microbiol       Date:  2020-05-22       Impact factor: 2.476

Review 5.  Sporothrix schenckii and Sporotrichosis.

Authors:  Mônica Bastos de Lima Barros; Rodrigo de Almeida Paes; Armando Oliveira Schubach
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

6.  Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis.

Authors:  Glaucia Francesconi; Antonio Carlos Francesconi do Valle; Sonia Lambert Passos; Mônica Bastos de Lima Barros; Rodrigo de Almeida Paes; André Luiz Land Curi; José Liporage; Cássio Ferreira Porto; Maria Clara Gutierrez Galhardo
Journal:  Mycopathologia       Date:  2010-11-21       Impact factor: 2.574

7.  Phenotypic and molecular characterisation of Sporothrix globosa of diverse origin from India.

Authors:  Shivaprakash M Rudramurthy; Shamanth A Shankarnarayan; Basavaraj M Hemashetter; Santwana Verma; Smriti Chauhan; Reema Nath; Jayanthi Savio; Malini Capoor; Harsimran Kaur; Anup K Ghosh; Arunaloke Chakrabarti
Journal:  Braz J Microbiol       Date:  2020-07-30       Impact factor: 2.476

8.  In vitro antifungal susceptibilities of five species of sporothrix.

Authors:  Rita Marimon; Carolina Serena; Josepa Gené; Josep Cano; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

9.  Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest.

Authors:  Rita Marimon; Josep Cano; Josepa Gené; Deanna A Sutton; Masako Kawasaki; Josep Guarro
Journal:  J Clin Microbiol       Date:  2007-08-08       Impact factor: 5.948

10.  Morphological and physiological comparison of taxa comprising the Sporothrix schenckii complex.

Authors:  Ming-dan Zhao; Xun Zhou; Ting-ting Liu; Zhi-bang Yang
Journal:  J Zhejiang Univ Sci B       Date:  2015-11       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.